
ACTUATE THERAPEUTICS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing cancer treatments, including its lead candidate elraglusib, a GSK-3β inhibitor being studied in combination with chemotherapy for pancreatic cancer and other solid tumors.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| SCHMITT DANIEL MPresident, CEO and Director | Buy | $50K | 140,844at $0.35 | Oct 28, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ACTU activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.